Đang chuẩn bị liên kết để tải về tài liệu:
Đánh giá hiệu quả và dung nạp của phác đồ tân bổ trợ trong điều trị ung thư dạ dày tiến triển tại chỗ

Mục tiêu: đánh giá hiệu quả và dung nạp của phác đồ tân bổ trợ trên bệnh nhân ung thư dạ dày (UTDD) tiến triển tại chỗ trong giai đoạn 2018-2020. Đối tượng nghiên cứu: 70 bệnh nhân được chẩn đoán xác định là UTDD tiến triển tại chỗ, được chỉ định điều trị phác đồ hóa trị tân bổ trợ ECX/ECF hoặc FLOT tại Bệnh viện K. | VNU Journal of Science Medical and Pharmaceutical Sciences Vol. 37 No. 4 2021 95-100 Original Article Effectiveness and Tolerance of Neoadjuvant Chemotherapy for Treatment of Locally Advanced Gastric Cancer Dao Van Tu1 Nguyen Khac Dung1 Nguyen Thi Ha2 Tran Thi Thu Hien3 Nguyen Thi Phuong Lan4 1 Vietnam National Cancer Hospital 30 Cau Buou Tan Trieu Thanh Tri Hanoi Vietnam 2 Hanoi University of Pharmacy 13-15 Le Thanh Tong Hoan Kiem Hanoi Vietnam 3 Hanoi University International Office Km 9 Nguyen Trai Thanh Xuan Hanoi Vietnam 4 VNU University of Medicine and Pharmacy 144 Xuan Thuy Cau Giay Hanoi Vietnam Received 17 August 2021 Revised 27 August 2021 Accepted 29 August 2021 Abstract This study aims to assess effectiveness and tolerance with neoadjuvant chemotherapy in patients with locally advanced gastric cancer in the period of 2018-2020. The study used the descriptive cross-sectional method to investigate 70 patients diagnosed with locally advanced gastric cancer assigned to ECX ECF or FLOT neoadjuvant chemotherapy regimens at Vietnam National Cancer Hospital. The results show that the partial response rates in the ECX ECF and FLOT groups were 69.70 and 89.20 respectively. There was no significant difference in the response level between the two groups p 0.716 . 78.79 in the ECX ECF group and 88.56 in the FLOT group underwent surgery. Neutropenia was an adverse event with the highest rate of grades 3 and 4 in both regimens FLOT regimen was 10.81 ECX ECF regimen was 24.24 . There is a statistically significant difference in the incidence of events between the groups with prophylaxis and non- prophylaxis by granulocyte colony-stimulating factor. Taken together there was no significant difference in the response level between the two groups regarding the event of neutropenia it could be controlled by prophylaxis in terms of benefits and risks for each patient. Keywords Gastric cancer effectiveness safety neoadjuvant chemotherapy. _ Corresponding author. E-mail .